Related Experiment Video
Updated: Aug 31, 2025
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture
Carlos García-Crespo1,2, Lucía Vázquez-Sirvent1,3, Pilar Somovilla1,4
1Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Abstract:
We report a quantification of the decrease of effectiveness of antiviral agents directed to hepatitis C virus, when the agents are added during an ongoing infection in cell culture vs. when they are added at the beginning of the infection. Major determinants of the decrease of inhibitory activity are the time post-infection of inhibitor administration and viral replicative fitness. The efficacy decrease has been documented with antiviral assays involving the combination of the direct-acting antiviral agents, daclatasvir and sofosbuvir, and with the combination of the lethal mutagens, favipiravir and ribavirin. The results suggest that strict antiviral effectiveness assays in preclinical trials may involve the use of high fitness viral populations and the delayed administration of the agents, relative to infection onset.
Insights
Antiviral drug effectiveness against hepatitis C virus decreases significantly when treatment begins after infection starts. Viral fitness and timing of administration are key factors influencing drug efficacy in cell cultures.
Area of Science:
- Virology
- Hepatitis C Virus (HCV) Research
- Antiviral Drug Development
Background:
- Hepatitis C virus (HCV) poses a significant global health challenge, necessitating effective antiviral therapies.
- Current antiviral drug effectiveness assays may not fully capture real-world treatment scenarios.
- Understanding factors influencing antiviral efficacy is crucial for optimizing treatment strategies.
Purpose of the Study:
- To quantify the reduction in effectiveness of antiviral agents against HCV when administered post-infection versus at infection onset.
- To identify key determinants influencing the decreased efficacy of antiviral agents.
- To inform the design of more rigorous preclinical antiviral effectiveness assays.
Main Methods:
- Cell culture models of hepatitis C virus infection were utilized.
- Antiviral assays were performed using combinations of direct-acting antiviral agents (daclatasvir and sofosbuvir) and lethal mutagens (favipiravir and ribavirin).
- The timing of antiviral agent administration (at infection onset vs. during ongoing infection) was a primary variable.
Main Results:
- A significant decrease in the effectiveness of antiviral agents was observed when administered during an ongoing HCV infection compared to at the beginning.
- The time of inhibitor administration post-infection and the replicative fitness of the virus were major determinants of this efficacy reduction.
- This phenomenon was consistently observed with both direct-acting antiviral combinations and lethal mutagen combinations.
Conclusions:
- The timing of antiviral agent administration is critical for determining treatment effectiveness against HCV.
- Viral replicative fitness plays a substantial role in modulating antiviral drug efficacy.
- Preclinical antiviral effectiveness assays should incorporate high-fitness viral populations and delayed agent administration to better predict in vivo performance.
